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The influence of health care spending 
on life expectancy
Health care expenditures and life expectancy have both 
been rising in many countries, including in the Netherlands. 
However, it is unclear to what extent increased health care 
spending caused the increase in life expectancy. Researchers 
have tried a variety of methods and data sources to establish 
a causal link between health care spending and life 
expectancy. This Panel Paper by Pieter van Baal (EUR), Parida 
Obulqasim (EUR), Werner Brouwer (EUR), Wilma Nusselder 
(Erasmus MC) and Johan Mackenbach (Erasmus MC) reviews 
these methods and data sources in order to investigate 
whether there is a causal link or not.

panel paper 35
Pieter van Baal, Parida Obulqasim, Werner Brouwer, 
Wilma Nusselder and Johan Mackenbach
The influence of health care 
spending on life expectancy
Colophon
Panel Papers is a publication of Netspar 
June 2013
Editorial Board
Roel Beetsma (Chairman) - University of Amsterdam
Bart Boon – Ministry of Finance
Eddy van Doorslaer – Erasmus University Rotterdam
Thomas van Galen – Cardano Risk Management
Kees Goudswaard – Leiden University
Winfried Hallerbach – Robeco Netherlands
Martijn Hoogeweegen – Nationale Nederlanden
Arjen Hussem – PGGM
Frank de Jong – Tilburg University
Alwin Oerlemans – APG
Marine Regnault-Stoel – AEGON Nederland
Maarten van Rooij – De Nederlandsche Bank
Peter Schotman – Maastricht University
Lou Spoor – Achmea
Peter Wijn – APG
Design
B-more Design
Bladvulling, Tilburg
Printing
Printing Office, Tilburg University
Editorial address
Netspar, Tilburg University
PO Box 90153, 5000 LE Tilburg
info@netspar.nl
No reproduction of any part of this publication may take place without permission 
of the authors.
Network for Studies on Pensions, Aging and Retirement
contents
Policy recommendations  11
Abstract 13
1. Introduction 14
2. Theoretical background 16
3. Review of empirical studies 29
4. Conclusions & discussion 42
References 46

 7
preface
Netspar stimulates debate and fundamental research in the field 
of pensions, aging and retirement. The aging of the population 
is front-page news, as many baby boomers are now moving 
into retirement. More generally, people live longer and in better 
health while at the same time families choose to have fewer 
children. Although the aging of the population often gets negative 
attention, with bleak pictures painted of the doubling of the ratio 
of the number of people aged 65 and older to the number of the 
working population during the next decades, it must, at the same 
time, be a boon to society that so many people are living longer 
and healthier lives. Can the falling number of working young 
afford to pay the pensions for a growing number of pensioners? 
Do people have to work a longer working week and postpone 
retirement? Or should the pensions be cut or the premiums paid 
by the working population be raised to afford social security for 
a growing group of pensioners? Should people be encouraged 
to take more responsibility for their own pension? What is the 
changing role of employers associations and trade unions in 
the organization of pensions? Can and are people prepared to 
undertake investment for their own pension, or are they happy 
to leave this to the pension funds? Who takes responsibility for 
the pension funds? How can a transparent and level playing field 
for pension funds and insurance companies be ensured? How 
should an acceptable trade-off be struck between social goals 
such as solidarity between young and old, or rich and poor, and 
individual freedom? But most important of all: how can the 
8benefits of living longer and healthier be harnessed for a happier 
and more prosperous society? 
 The Netspar Panel Papers aim to meet the demand for 
understanding the ever-expanding academic literature on the 
consequences of aging populations. They also aim to help give 
a better scientific underpinning of policy advice. They attempt 
to provide a survey of the latest and most relevant research, 
try to explain this in a non-technical manner and outline the 
implications for policy questions faced by Netspar’s partners. Let 
there be no mistake. In many ways, formulating such a position 
paper is a tougher task than writing an academic paper or an 
op-ed piece. The authors have benefitted from the comments of 
the Editorial Board on various drafts and also from the discussions 
during the presentation of their paper at a Netspar Panel Meeting. 
 I hope the result helps reaching Netspar’s aim to stimulate 
social innovation in addressing the challenges and opportunities 
raised by aging in an efficient and equitable manner and in an 
international setting.
Roel Beetsma
Chairman of the Netspar Editorial Board
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the influence of health care 
spending on life expectancy
Policy recommendations 
Developed countries spend an increasing portion of their Gross 
Domestic Product (GDP) on health care with the aim to improve 
population health. However, as the percentage of GDP that is 
spent on health care increases, this raises concerns about the rate 
of return on these investments. In this Netspar panel paper, we 
summarize the findings of studies that have tried to establish a 
causal link between health care spending and health outcomes 
as measured by mortality and/or life expectancy. The focus on 
mortality and life expectancy is relevant for both policymaking 
and the Netspar initiative. One of the major threats to the 
sustainability of pension systems in the Netherlands is the 
unexpectedly rapid growth of life expectancy in recent years. 
If this increase is, in fact, a result from additional health care 
spending, this raises important inter-sectoral policy questions. 
For instance, for the affordability of future pensions it is relevant 
to know whether further increases in health care spending are 
likely to lead to further increases in life expectancy. If health care 
is found to have a strong influence on life expectancy, expanding 
health care spending then also has consequences for public 
provisions like social insurance and for pension liabilities. 
 Based on our literature review, we conclude that, although a 
causal influence of health care spending on life expectancy has 
been difficult to demonstrate in empirical studies, it is highly 
likely that increases in health care expenditures have contributed 
to the growth of life expectancy in Western countries. This 
conclusion has several implications for the Netherlands. Since 
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health care spending has increased in the Netherlands, a part 
of this increase has probably resulted in higher life expectancy, 
which in turn may have had its repercussions on public finance. 
However, the exact impact of health care spending on life 
expectancy growth in the Netherlands is difficult to pinpoint. 
Applying the estimates from published studies to the observed 
increase in health care spending in the Netherlands between 
2000 and 2010 would imply that 0.3% to almost 50% (1.6 years) 
of the increase in life expectancy is caused by increasing health 
care spending. If the influence of health care spending on life 
expectancy is at the higher end of these estimates, increased 
health care spending will have had a clear impact on pension 
funds. After all, a one-year increase in life expectancy at 
retirement age increases pension liabilities by 3 to 4 percent. 
If we extrapolate these findings into the future, this would 
imply that additional investments in the health care sector may 
cause further increases in life expectancy. As the strength of the 
effect of health care expenditures on life expectancy is rather 
uncertain, strong policy recommendations are difficult to give. 
Given the age profile of mortality risk, gains in life expectancy 
through increased health care spending will probably be reached 
through decreasing mortality rates at higher ages. Increases in life 
expectancy at higher ages may create an additional demand for 
health care but also imply an increase in pension liabilities. Based 
on these consequences within and outside the health care sector, 
it is important that, when evaluating new medical technologies 
that are known to extend life, costs of increased life expectancy 
are included, but that is currently not done. If further research 
allows better quantification of the strength of the effect of health 
care spending on life expectancy, the role of such spending as a 
determinant of mortality could be acknowledged when making 
forecasts of life expectancy. 
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Abstract
Health care expenditures and life expectancy have both been 
rising in many countries, including in the Netherlands. However, 
it is unclear to what extent increased health care spending caused 
the increase in life expectancy. Establishing a causal link between 
health care expenditures and mortality is difficult for several 
reasons. In medicine, randomized clinical trials are the gold 
standard to demonstrate causality and thereby the effectiveness 
of clinical interventions. However, data from randomized 
trials are not available to estimate the influence of health care 
spending on life expectancy. As a result, researchers have tried 
a variety of methods and data sources to establish a causal link 
between health care spending and life expectancy. Our review of 
empirical studies revealed nonetheless that a causal influence of 
marginal increases in health care spending has been difficult to 
demonstrate in empirical research, given all methodological issues 
surrounding the estimates of empirical studies. We conclude 
therefore that, while it appears likely that increases in health 
care spending have contributed somewhat to the growth in life 
expectancy in Western countries, the strength of the effect remains 
uncertain and may differ between sectors. Also, the mechanisms 
underlying the causal relationship between health care spending 
and life expectancy are still unclear. For instance, both the role of 
specific medical technologies and that of health care reforms seem 
important in this context, but especially regarding the role of 
health care reforms sound evidence is lacking. Therefore, further 
research in this area, which would profit from new data sources 
and increased possibilities for data linkage, as well as further 
developments of the methods to exploit these, remain needed. 
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1. Introduction
Recent increases in health care expenditures in the Netherlands, 
possibly caused by health care system reforms, were accompanied 
by an increase in life expectancy (especially life expectancy 
at older ages), suggesting a causal relation between the two 
(Mackenbach et al. 2011). A central question in the Netspar 
theme ‘Causes and consequences of rising life expectancy in the 
Netherlands’ is whether recent increases in life expectancy are 
indeed caused by increased health care spending. In this Netspar 
panel paper, we will summarize the findings of studies that have 
tried to establish a causal link between health care expenditures 
and health outcomes as measured by mortality and/or life 
expectancy. 
 We will try to answer the following research question in this 
paper:
– Is there evidence that health care expenditures are a causal 
determinant of life expectancy? 
– Along the way we will also address the following related 
research questions:
– What types of health care spending have affected life 
expectancy? For instance, is there evidence that increases in 
spending in specific health care sectors (e.g. hospital care) 
have affected mortality, or was it spending targeted at specific 
disease groups (e.g. cancer)? 
– What is known about the effects of health care spending on 
particular subgroups? For instance, did health care spending 
mainly affect mortality of the young or instead of the old?
–  Is there evidence that interventions at the macro level (e.g. 
health system reforms) that impact health care spending also 
impact life expectancy? 
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 This paper is structured as follows. First, we will present some 
background describing the conceptual relations between health 
care spending and mortality. In this section we will first argue 
that an increase in health care spending does not necessarily 
lead to an increase in life expectancy. Second, we will describe 
the difficulties encountered in establishing a causal relation 
between health care spending and mortality. Third, we will 
give an overview of studies that have tried to establish a link 
between health care spending and life expectancy, and translate 
the findings of these studies to the Dutch context. The paper 
concludes with a summary of our findings and suggestions for 
future research. 
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2. Theoretical background
Medical care and mortality
Life expectancy has been on the rise in most Western countries 
since the nineteenth century. The question whether medical 
care has played an important role in this rise has been a topic of 
intense scientific debate (Nolte and McKee 2004). Until the 1950s 
it was assumed that medical care has contributed substantially 
to the observed mortality decrease, mainly through effective 
combating of infectious diseases. However, Thomas McKeown 
challenged this common wisdom. He published several studies in 
which he demonstrated that the decline in mortality of infectious 
diseases preceded the introduction of effective medical therapies 
for these diseases.1 From this, McKeown concluded that medical 
care has not made a substantial contribution to the mortality 
decline since the middle of the nineteenth century until the 
1950s. Although some of the conclusions drawn by McKeown have 
been questioned (especially his conclusion that improvements 
in longevity were mainly the result of improved living standards 
leading to better nutrition), the importance of his work should 
not be underestimated (Mackenbach 1996; Bunker 2001). An 
important lesson from the work of McKeown is that it cannot be 
automatically assumed that more medical care always leads to an 
increase in life expectancy. 
 Since the 1950s causes of death have changed from mainly 
infectious diseases to chronic diseases, and medical care has 
changed in response to this epidemiological transition (Cutler 
et al. 2006). Inspired by the work of McKeown, researchers have 
investigated whether causes of death that are amenable to 
1 McKeown’s work is summarized in his much cited book, ‘The Role of Medicine 
– Dream, Mirage or Nemesis’ (McKeown 1979).
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medical care have declined since the 1950s (Nolte and McKee 
2004; Mackenbach et al. 1988). The main conclusion from this line 
of research is that medical care has contributed to the increase 
in life expectancy in Western countries since the 1950s. Some 
studies have gone a step further. They have argued not only that 
medical care is an important cause of increased life expectancy, 
but also that the investments in medical care were good value 
for money (Meerding et al. 2007; Cutler et al. 2006; Cutler and 
McClellan 2001). Using published evidence on the effectiveness 
of specific preventive and curative interventions within the 
health care sector, these studies have tried to construct a 
counterfactual to estimate life expectancy in the absence of these 
interventions. This counterfactual situation involves the absence 
of medical curative care and/or of various forms of prevention, 
such as medication to lower blood pressure and cholesterol 
levels, vaccinations, and early detection of diseases (screening). 
Differences between observed life expectancy and counterfactual 
life expectancy were then related to the costs of the various 
interventions in order to assess whether the interventions offered 
value for money. 
 Cutler and McClellan (Cutler et al. 2006) estimated the costs and 
benefits of medical technology for five health conditions in the 
US by combining data from several sources. They concluded that 
‘the benefits from lower infant mortality and better treatment 
of heart attacks have been sufficiently great that they alone are 
about equal to the entire cost increase for medical care over time’. 
For the Netherlands, Meerding et al. (2007) combined historical 
data on incidence and mortality for infectious diseases, cancer, 
and cardiovascular disease with information about the year in 
which specific medical innovations were introduced to construct 
counterfactuals. Based on their analyses, they concluded that 
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medical care has contributed to approximately 50% of the seven-
year increase in life expectancy since the 1950s. The yield per euro 
spent on health care, however, varied substantially from one 
disease group to another (from € 3,100 spent per life year gained 
for cardiovascular diseases to € 15,000 per life year gained for 
cancer). 
 Against the backdrop of this literature, it is very likely that 
medical care on balance has contributed to the high levels of life 
expectancy witnessed today in many countries. However, this 
in itself does not imply that marginal increases in health care 
spending will further increase life expectancy. 
The benefits of increasing health care spending
Health care spending can be broadly defined as the amount of 
money spent by individuals and private and public organizations 
for health care and its various components such as surgeries, 
therapies and medication. Health care spending encompasses 
amounts related to different health care providers such as 
hospitals and general practitioners, but it also includes expenses 
related to providers of long-term care.2 
  At the societal level, the most important determinants of 
health care spending are GDP, medical technology, and health care 
system features (Koopmanschap et al. 2010). In the Netherlands, 
for instance, recent increases in health care spending were partly 
due to changes in the way health care providers were reimbursed 
(Van de Vijsel et al. 2011). 
2 It is important to note that differences in health care expenditures between 
countries are partly caused by different definitions of health care. Sometimes 
health care facilities that exist in one country do not exist in other countries 
(e.g. homes for the elderly in the Netherlands). Furthermore, definitions of the 
health care system differ between countries: some facilities are considered part 
of the health care system in some countries, while they are excluded in others.
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 An increase in health care expenditures may be the result of 
an increase of health care volume and/or of the price of health 
care. Both mechanisms may positively impact life expectancy. An 
increase in the volume of health care may imply a higher coverage 
of medical care, a reduction of waiting lists, or that new effective 
treatments have been implemented. An increase in price may be 
the result of implementation of new (more expensive) effective 
technologies, but also of higher wages, which in turn may result 
in a more efficient delivery of health care. All these different 
mechanisms make clear that the effect of higher health care 
spending will be largely determined by the cause of the higher 
spending. Sudden changes in the growth of health care spending 
may be caused by reforms in the health care sector, and that may 
have differential effects on life expectancy, depending on the 
type of reform. One may hypothesize that an increase in health 
care spending resulting from a change to output-based financing 
of hospitals has a different effect on mortality compared to an 
increase in health care spending due to an expansion of long-
term care facilities. For the purpose of this paper it is useful to 
distinguish between effects of health care spending on mortality 
at the micro level (e.g. through new medical technology) versus 
effects of health care spending on mortality at the macro level 
(e.g. through health system reforms). 
 The impact of health care spending on mortality has been 
studied extensively on a micro level for isolated medical 
interventions in strictly defined patient groups. Nowadays, in 
some countries, before new medical technologies (new drugs, 
diagnostic technologies etc.) will be reimbursed by insurers or 
adopted by health care providers, it must be demonstrated that 
these new technologies offer value for money (O’Donnell et al. 
2009). To demonstrate such value for money, a cost effectiveness 
20 panel paper 35
analysis is usually conducted. In such cost effectiveness analysis, 
evidence regarding the effectiveness of, for instance, a new drug 
(mostly coming from randomized clinical trials) is combined with 
cost and quality-of-life data to estimate the costs and benefits 
of a well-defined intervention. Cost effectiveness is typically 
expressed as an incremental cost effectiveness ratio (ICER), the 
ratio of change in costs to the change in effects (Drummond et 
al. 2005). Costs refer to the resources used for the intervention, 
usually measured in monetary terms such as dollars or euros. The 
measure of effects depends on the intervention being considered. 
For life-saving interventions, effects are usually expressed in 
life years gained. Sometimes the effects are measured using 
quality-adjusted life years (QALY) or disability-adjusted life years 
(DALY); that also includes the impact of interventions on non-fatal 
health outcomes. Important characteristics of cost-effectiveness 
analyses are that they are conducted ex-ante on a micro level and 
that incremental costs and effects due to a single intervention are 
the central outcome measures. This contrasts with the empirical 
research discussed in this paper, where the average returns of 
health care spending (usually a mix of different technologies) in 
terms of life expectancy are estimated ex-post using mostly macro 
level (aggregated) data. 
 Even though evidence-based analyses of medicine and cost 
effectiveness have become more important over the years, they 
do not provide sufficient evidence that more health care spending 
does lead to an increase in life expectancy. There are several 
reasons for this, as follows: 
1. Not all medical care is intended to reduce mortality. Rather, 
it may be intended to increase the quality of life or to reduce 
disabilities. For instance, in the Netherlands a large share of 
health care spending is on treatment of mental diseases which, 
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for a large part, are non-fatal (Slobbe et al. 2006; Poos et al. 
2008). Therefore, if additional health care spending is mainly 
caused by expanding care for non-lethal diseases, this could 
possibly increase population health while life expectancy 
remains unaltered. 
2. Wages in the health care sector may increase without causing 
any productivity gains (so-called Baumol’s disease), thus 
leaving mortality unaffected (Pomp and Vujic´ 2008). 
3. Not all medical care is based on solid scientific evidence, and 
expenditures can rise because of an increase in the use of non-
effective procedures. 
4. Even if there is evidence on medical interventions, findings 
from clinical trials do not always predict well how some medical 
interventions work in practice (Flather et al. 2006). Patients in 
clinical trials are often recruited using strict inclusion criteria 
(e.g. non-smoking, no co-morbidities) and do not resemble 
real life populations. In daily practice, interventions are offered 
to populations that differ from the patients included in a trial 
(broader indication areas, other age categories, persons with 
co-morbidity). Furthermore, adherence to treatment protocols 
is usually much better in clinical trials than in daily practice. 
5. Even if effective life-prolonging interventions are implemented 
in practice, it can occur that other effective life-prolonging 
interventions are displaced. If the displaced activities were 
more cost-effective than the newly implemented interventions, 
an increase in health care spending may even result in 
increased mortality (McCabe et al. 2008). 
Health care expenditures and mortality: methodological issues
Although health care spending and life expectancy have generally 
both been on the rise in Western countries in the past several 
22 panel paper 35
decades (OECD 2006), it is difficult to isolate the contribution 
of medical care to this increasing life expectancy. Given the 
impossibility of randomized controlled clinical trials, establishing 
a causal link between health care spending and life expectancy 
is difficult for several reasons. First, life expectancy is determined 
by many factors varying over time and place, which makes it hard 
to adjust for all the potential external influences on mortality 
other than medical care. Second, there may be time lags between 
health care spending and its effects on health. Finally, there 
Figure 1: Life expectancy at birth plotted as a function of total 
health care spending per capita in 2008. 
Source: OECD (2010), OECD Health Data 2010, OECD Publishing, Paris 
(www.oecd.org/health/healthdata).
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is the issue of reverse causality since increased longevity may 
create additional health care demand as people live longer. In 
this section we will briefly discuss these issues. This will help to 
understand better the methodological approaches and findings of 
the empirical studies in the next chapter.3  
Confounders
In general, it is observed that countries with higher health care 
spending also have a higher life expectancy. 
 Figure 1 clearly demonstrates a correlation between health care 
spending and life expectancy. However, this correlation does not 
necessarily imply a causal relationship running from health care 
spending to life expectancy. As life expectancy is determined by 
many factors, one would have to correct for many confounders 
including life style factors (e.g. smoking) and environmental 
factors (e.g. air pollution) to assess the role of health care 
spending. An important confounder within the context of the 
impact of health care spending on life expectancy is GDP. It has 
long been known in the field of health economics that GDP is the 
most important determinant of macro-level health care spending 
(Gerdtham and Jönsson 2000). Given the high correlation 
between GDP and health care spending, we would get a similar 
pattern as in Figure 1 when plotting gross national product 
(GDP) on the x-axis instead of health care spending. It has been 
argued that a higher GDP in itself is an important determinant 
of life expectancy, independent of its effect through increased 
3 Counterfactual studies, mentioned at the beginning of this chapter, do not 
estimate the impact of health care spending directly but indirectly, using data 
from other studies or expert knowledge. Therefore, issues related to 
confounders, reverse causality, and time lags were not addressed in these 
counterfactual studies, but only in the studies used to construct the 
counterfactuals.
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health care spending (McKeown 1979). As discussed, reductions 
in mortality which took place from the second half of the 19th 
century onwards were, for the most part, the result of a healthier 
living environment (improved drinking water facilities, drains, 
and sewers), a better hygiene, and diet. To better understand the 
role of GDP as confounder, Figure 2 displays a simple causal chain 
from GDP to mortality.
  GDP impacts many other determinants of mortality besides 
health care spending. A higher GDP may imply better nutrition, 
more extensive educational opportunities, better road safety, 
ability to buy better cars, etc. For our purposes, we are only 
interested in the solid black arrow in Figure 2. However, this can 
only be estimated if one properly adjusts for the other arrows in 
Figure 2. GDP is obviously not the only confounder. For instance, 
life-style habits (especially smoking) are important confounders 
as well (even though not necessarily related to GPD). Furthermore, 
the relevant confounders also depend on the level of aggregation 
of the data. For data at population level, GDP is of course an 
important confounder. However, for studies using regional data 
GDP is less relevant, and other confounders may then become 
more important. 
Mortality/Life 
expectancy
Health care 
expenditures
Sanitation, nutrition, 
road safety, etc.
GDP 
Figure 2: Simple causal chain from GDP to mortality 
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Time lags 
In Figure 1, we saw a strong relation between health care spending 
and life expectancy. The graph plots current health care spending 
against current mortality. However, current mortality rates are 
probably also influenced by health care spending in the past. 
While some medical interventions have an immediate effect 
(e.g. better trauma care, blood pressure medication), other 
medical interventions only influence mortality in the longer run. 
Figure 3: Changes in life expectancy at birth between 1998 
and 2008 plotted as a function of changes in total health care 
spending per capita. 
Source: OECD (2010), OECD Health Data 2010, OECD Publishing, Paris 
(www.oecd.org/health/healthdata)
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Examples are screening for cancer (Tabar et al. 2003), which has 
consequences in the distant future, but also diabetes treatment 
(Malmberg 1997). Figure 3 plots changes in life expectancy against 
changes in health care spending. It suggests that countries with a 
larger increase in health care spending also witnessed a sharper 
increase in life expectancy. This suggests that there are immediate 
causal effects of health care spending on mortality. 
Reverse causality 
While this panel paper focuses on the causal influence of health 
care spending on life expectancy, a large body of research within 
health economics has focused on the reverse causal mechanism: 
the causal influence of life expectancy on health care spending. 
Many studies have investigated whether the demand for health 
care increases with increasing longevity. In these studies, 
health care spending was the dependent variable instead of an 
explanatory variable. Figure 4 extends Figure 2 by allowing for 
reverse causality. 
Mortality/Life 
expectancy
Health care 
expenditures
Sanitation, nutrition, 
road safety, etc.
GDP 
Figure 4: Causal chain running from GDP to mortality and back 
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 Reverse causality running from mortality to health care 
spending can follow two paths. First, there is an indirect path, 
by which an increase in life expectancy may increase GDP and 
thereby increase health care spending. It has been argued that 
improvements in life expectancy have led to economic growth 
(Bhargava et al. 2001; Swift 2010), which may have caused an 
increase in health care expenditures since economic growth is an 
important determinant of health care spending. Second, there 
is a direct link in the sense that if people live longer, they are 
likely to need health care for a longer period of time. A higher 
life expectancy means more people surviving (either healthy or 
with disease), getting older, and being exposed to other diseases 
(substitute morbidity), which leads to need for cure and care. This 
second path has been much studied within the context of the 
Figure 5: Per capita health care expenditures by gender and age in 
the Netherlands in 2007 according to the definition of health care 
spending of the System of Health Accounts 
Source: RIVM Costs of Illness
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economic consequences of population aging. To understand the 
rationale of why so much research is carried out on the effects of 
aging on health care expenditures, Figure 5 displays per capita 
health care expenditures for different age categories in the 
Netherlands.
 In Figure 5, we can see that health care spending strongly 
increases with age. This figure therefore suggests that an increase 
in life expectancy leads to an increase in health care spending. 
However, although the growing number of elderly people enlarges 
the group of individuals in need of health care, the question 
whether longevity gains increase health care spending has been 
subject to debate (Zweifel et al. 1999; Salas and Raftery 2001; 
Getzen 2001; Seshamani and Gray 2004; Felder et al. 2009; Van 
Baal and Wong 2012). Zweifel et al. (1999) argued that differences 
in health care spending between individuals can be better 
explained by time to death (TTD) than time since birth (age). In 
their view, the steep increase in health care spending by age is 
mainly the result of the steep increase in mortality with age. With 
respect to the question whether increased longevity increases 
health care spending, the TTD theory has strong implications. If 
we account for the fact that individual health care consumption 
concentrates during the period before death, an increase in life 
expectancy does not strongly increase the demand for health care 
as most of health care demand is merely postponed (Payne et al. 
2007). In this sense the strength of the reverse causality effect may 
be weaker than originally thought, even though it is not absent 
as, for instance, long-term care in contrast with cure still shows a 
strong relation with age, when taking into account time to death 
(Koopmanschap et al. 2010). 
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3. Review of empirical studies 
In the previous section, we described three issues that arise 
when one wants to investigate the causal influence of health care 
expenditures on mortality/life expectancy. First, there are many 
other determinants of mortality besides health care expenditures 
that have to be considered. Second, there may be a time lag 
between health care spending and its effects on mortality. Finally, 
there is the issue of reverse causality in the sense that current 
health care spending is to some extent influenced by current 
levels of mortality as well as past levels of mortality. Although 
some methodological issues depend on the type of data used, 
there are some general issues that are worth mentioning in the 
context of this paper. These issues are clearly discussed by Gravelle 
and Backhouse (1987). Primarily, to deal with confounders and 
reverse causality, they proposed to first specify a health production 
function based on theory. They demonstrate that specifying a 
production function allows modeling of the different causal 
paths that govern the relation between health care spending and 
mortality. As the data in this area of research do not come from 
trials which were set up with pre-specified hypotheses, Gravelle 
and Backhouse argue that conducting statistical analyses without 
first specifying a theoretical model “leads to a theoretical search 
for measures demonstrating statistically ‘significant’ associations 
with health outcomes.” 
 In this section, we will summarize the findings of empirical 
studies that have tried to estimate the causal influence of health 
care spending on life expectancy and/or mortality. As a starting 
point, we have taken the review studies by Nolte and McKee 
(2004), Nixon and Ulmann (2006) and Grootendorst, Piérard, and 
Shim (2009). From these review studies, we will only discuss the 
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studies that included health care spending as an independent 
variable. Within the context of this paper, we will focus exclusively 
on health care spending, which is the product of the volume 
and the price of care. Economic as well as medical journals were 
searched for studies that are more recent. We will subdivide this 
chapter on the empirical findings into sections depending on 
the type of methods and data used. We will start by discussing 
studies that have used data aggregated at country level, in order 
to investigate whether there is a relation between life expectancy/
mortality and health care spending after correcting for various 
confounders. After that, we will discuss studies exploiting regional 
variations in health care spending and mortality within countries 
to estimate the effect of health care spending. Then we will 
describe a study that has used individual level data. In these 
sections, we will where possible translate the findings of the 
studies to the Dutch context. 
Cross-country comparisons
In cross-country studies, indicators of mortality (e.g. life 
expectancy at birth, infant mortality, and/or causes of 
mortality amenable to health care) are regressed on a number 
of explanatory variables including health care spending. An 
important caveat of using cross-country data relates to the 
measurement of health care spending. Besides differences in what 
constitutes health care, there are problems in trying to convert 
health expenditures into a common currency. Some studies have 
used Purchasing Power Parities (PPP) for GDP to accomplish this, 
while other studies have used PPPs that are specific to health 
care. However, it has been argued that differences in inflation 
between the health care sector and other sectors are (at least 
partly) amenable to health policy and should therefore not be 
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corrected for. The studies used either data coming from a single 
year or from multiple years (also called panel data or longitudinal 
data). Compared to a single cross section of different countries, 
panel/longitudinal data offer richer information, but they also 
pose additional methodological challenges. Particularly, statistical 
issues associated with time series such as serial correlation should 
be adequately dealt with. 
Total health care spending 
Most studies involving cross-country data have used data from 
OECD countries, where health care spending is measured according 
to the System of Health Accounts definition. This definition of 
health care spending encompasses hospital care, pharmaceuticals, 
general practitioners, and long-term care (Orosz and Morgan 
2004). Table 1 displays an overview of studies at country level 
that have used per capita health care spending (according to the 
System of Health Accounts) as predictor variable and mortality 
or life expectancy as outcome variable. To bring the results of 
these studies down to a common denominator, we translated the 
results of each study to the Dutch context. That meant taking the 
changes in per capita health care spending in the Netherlands 
between 2000 to 2010 (a 40% increase from roughly € 3,700 to 
€ 5,300, adjusted for inflation and expressed in 2010 prices) and 
applying the empirical estimates of the studies to estimate their 
contribution to the observed increase in life expectancy in the 
Netherlands. Dutch life expectancy at birth increased from 75.5 
to 78.8 years for men and from 80.6 to 82.7 years for women 
between 2000 and 2010. The changes in life expectancy resulting 
from the increase in health care spending, estimated in this way, 
are displayed in the last column. 
32 panel paper 35
Study & 
Data
Data Outcome 
measures
Confounding variables included Main findings How would life expectancy have changed in the 
Netherlands between 2000 and 2010 based on 
estimated effect of health care spending? 
Wolfe and 
Gabay 
(1987)
22 OECD countries  
for three years: 1960, 
1970, and 1980.
LE at birth;  
LE at age 
60; infant 
mortality 
rate; pre natal 
mortality rate.
GDP; butter consumption; road accidents; liver 
cirrhosis (female and male); tobacco consump-
tion; employment in safe and risky industry. 
Increase in medical spending leads to a signifi-
cant improvement in female life expectancy. 
Other indicators of mortality were not signifi-
cantly related to health care spending (HCE). 
0.01 year increase in LE for men (0.3% of 
the observed increase in the Netherlands);
0.2 year increase in LE for women (8.7% of 
the observed increase in the Netherlands)
Hitiris 
and  
Posnett 
(1992)
Annual time-series 
data on 20 OECD 
countries covering 
the 1960-1987 
period. 
Crude  
mortality  
rates.
GDP per capita; percentage 65+. Health care spending significantly decreases 
crude mortality rates. A 10% increase in HCE 
decreases crude mortality rates by 0.8%. 
0.6 year increase in LE for men (17.2% of 
the observed increase in the Netherlands);
0.3 year increase in LE for women (13.6% of 
the observed increase in the Netherlands)
Elola, et 
al. (1995) 
Cross-sectional 
data on 17 Western 
European countries 
in 1990 or 1991. 
LE at birth; 
life years lost; 
infant mortal-
ity rate. 
GDP per capita; dummy variable of health care 
system; percentage of population covered by 
health care system; Gini coefficient. 
Only infant mortality was significantly negatively 
related to health care spending. Other indicators 
of mortality were not significantly related to HCE. 
A 10% increase in HCE decreases infant mortality 
rates by 2.6%.
0.1 year increase in LE for men (1.8% of 
the observed increase in the Netherlands);
0.1 year increase in LE for women (3.0% of 
the observed increase in the Netherlands)
Or (2000) Annual time-series 
data on 21 OECD 
countries over the 
1970-1992 period.
Premature 
mortality; life 
years lost
GDP per capita; share of white-collar workers 
in total work force; NOx emissions per capita; 
consumption of alcohol; consumption of tobacco 
per capita; fat (butter) consumption per capita; 
sugar consumption per capita. 
Heath spending was only significantly related to 
premature mortality for women. A 10% increase 
in HCE decreases premature mortality for women 
by 1.8%.
For this study it was not possible to translate 
findings to the Dutch context as it was not clear 
from the paper how premature mortality was 
calculated. 
Berger 
and 
Messer 
(2002)
Annual time-series 
on 20 OECD countries 
over the 1960-1992 
period.
Overall mor-
tality rate per 
1000 inhabit-
ants.
GDP; % 65+; tobacco, alcohol & animal fat 
consumption; female labor force participation; % 
higher education; Gini coefficient; % eligible for 
in-patient care benefits; % eligible for ambula-
tory care benefits under a public scheme.
Health care spending has a significant negative 
effect on overall mortality. A 10% increase in HCE 
decreases overall mortality rates by 1.3%.
0.9 year increase in LE for men (27.5% of 
the observed increase in the Netherlands)
0.5 year increase in LE for women (21.7% of 
the observed increase in the Netherlands)
Nixon 
and 
Ulmann 
(2006)
Annual time-series 
data on 15 EU 
countries over the 
1980-1995 period.
LE at birth; 
infant mor-
tality. 
Number of physicians, hospital beds; patient 
admission rate; average patient length-of-stay; 
population coverage of health care system; 
unemployment rate; alcohol & tobacco consump-
tion; several nutritional variables; environmental 
pollution.
Health care spending has a positive impact on 
both male and female LE at birth, and negative 
impact on infant mortality rate. A 1% increase in 
health care spending increases life expectancy at 
birth by 0.02% for both males and females.
0.7 year increase in LE for men (22.1% of 
the observed increase in the Netherlands)
0.8 year increase in LE for women (35.8% of 
the observed increase in the Netherlands)
Heijink et 
al. (2012)
Annual time-series 
on 14 OECD countries 
over the 1996-2006 
period.
Total avoidable 
mortality 
per 100,000 
inhabitants
Age structure; mortality not amenable to health 
care; GDP; education; unemployment rate; 
alcohol and tobacco consumption
A 1% increase in health care spending decreased 
avoidable mortality by 0.11%. 
0.3 year increase in LE for men (8.0% of 
the observed increase in the Netherlands)
0.3 year increase in LE for women (13.9% of 
the observed increase in the Netherlands)
Table 1: Summary of findings from empirical studies using panel data from  
different countries with health care expenditures as independent variable 
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Study & 
Data
Data Outcome 
measures
Confounding variables included Main findings How would life expectancy have changed in the 
Netherlands between 2000 and 2010 based on 
estimated effect of health care spending? 
Wolfe and 
Gabay 
(1987)
22 OECD countries  
for three years: 1960, 
1970, and 1980.
LE at birth;  
LE at age 
60; infant 
mortality 
rate; pre natal 
mortality rate.
GDP; butter consumption; road accidents; liver 
cirrhosis (female and male); tobacco consump-
tion; employment in safe and risky industry. 
Increase in medical spending leads to a signifi-
cant improvement in female life expectancy. 
Other indicators of mortality were not signifi-
cantly related to health care spending (HCE). 
0.01 year increase in LE for men (0.3% of 
the observed increase in the Netherlands);
0.2 year increase in LE for women (8.7% of 
the observed increase in the Netherlands)
Hitiris 
and  
Posnett 
(1992)
Annual time-series 
data on 20 OECD 
countries covering 
the 1960-1987 
period. 
Crude  
mortality  
rates.
GDP per capita; percentage 65+. Health care spending significantly decreases 
crude mortality rates. A 10% increase in HCE 
decreases crude mortality rates by 0.8%. 
0.6 year increase in LE for men (17.2% of 
the observed increase in the Netherlands);
0.3 year increase in LE for women (13.6% of 
the observed increase in the Netherlands)
Elola, et 
al. (1995) 
Cross-sectional 
data on 17 Western 
European countries 
in 1990 or 1991. 
LE at birth; 
life years lost; 
infant mortal-
ity rate. 
GDP per capita; dummy variable of health care 
system; percentage of population covered by 
health care system; Gini coefficient. 
Only infant mortality was significantly negatively 
related to health care spending. Other indicators 
of mortality were not significantly related to HCE. 
A 10% increase in HCE decreases infant mortality 
rates by 2.6%.
0.1 year increase in LE for men (1.8% of 
the observed increase in the Netherlands);
0.1 year increase in LE for women (3.0% of 
the observed increase in the Netherlands)
Or (2000) Annual time-series 
data on 21 OECD 
countries over the 
1970-1992 period.
Premature 
mortality; life 
years lost
GDP per capita; share of white-collar workers 
in total work force; NOx emissions per capita; 
consumption of alcohol; consumption of tobacco 
per capita; fat (butter) consumption per capita; 
sugar consumption per capita. 
Heath spending was only significantly related to 
premature mortality for women. A 10% increase 
in HCE decreases premature mortality for women 
by 1.8%.
For this study it was not possible to translate 
findings to the Dutch context as it was not clear 
from the paper how premature mortality was 
calculated. 
Berger 
and 
Messer 
(2002)
Annual time-series 
on 20 OECD countries 
over the 1960-1992 
period.
Overall mor-
tality rate per 
1000 inhabit-
ants.
GDP; % 65+; tobacco, alcohol & animal fat 
consumption; female labor force participation; % 
higher education; Gini coefficient; % eligible for 
in-patient care benefits; % eligible for ambula-
tory care benefits under a public scheme.
Health care spending has a significant negative 
effect on overall mortality. A 10% increase in HCE 
decreases overall mortality rates by 1.3%.
0.9 year increase in LE for men (27.5% of 
the observed increase in the Netherlands)
0.5 year increase in LE for women (21.7% of 
the observed increase in the Netherlands)
Nixon 
and 
Ulmann 
(2006)
Annual time-series 
data on 15 EU 
countries over the 
1980-1995 period.
LE at birth; 
infant mor-
tality. 
Number of physicians, hospital beds; patient 
admission rate; average patient length-of-stay; 
population coverage of health care system; 
unemployment rate; alcohol & tobacco consump-
tion; several nutritional variables; environmental 
pollution.
Health care spending has a positive impact on 
both male and female LE at birth, and negative 
impact on infant mortality rate. A 1% increase in 
health care spending increases life expectancy at 
birth by 0.02% for both males and females.
0.7 year increase in LE for men (22.1% of 
the observed increase in the Netherlands)
0.8 year increase in LE for women (35.8% of 
the observed increase in the Netherlands)
Heijink et 
al. (2012)
Annual time-series 
on 14 OECD countries 
over the 1996-2006 
period.
Total avoidable 
mortality 
per 100,000 
inhabitants
Age structure; mortality not amenable to health 
care; GDP; education; unemployment rate; 
alcohol and tobacco consumption
A 1% increase in health care spending decreased 
avoidable mortality by 0.11%. 
0.3 year increase in LE for men (8.0% of 
the observed increase in the Netherlands)
0.3 year increase in LE for women (13.9% of 
the observed increase in the Netherlands)
(health care expenditures according to the ‘system of health accounts’ definition)
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From Table 1 we can see that most studies found a significant 
effect of total health care spending on mortality or life expectancy. 
The weakest effects were found in the study by Elola et al., who 
used only one cross-section of data. Results from the other 
studies, which used data from multiple years, indicate that 
changes in health care spending are associated with changes 
in life expectancy even when adjusted for confounders. The 
last column of the table displays estimates of how much life 
expectancy would have increased if the study findings were 
applied to the observed 40% increase in health care spending 
between 2000 and 2010 in the Netherlands. From this column 
we can see that there is a wide variation in the estimated effect 
of health care spending on life expectancy, ranging from 0.3% 
to 35.8%. This corresponds to an average cost effectiveness of 
the increase in health care spending ranging from € 167,000 to 
€ 2,000 per life year gained. It should be noted that in most 
studies described in Table 1 only contemporaneous effects of 
health care spending on mortality were estimated. Only Heijink et 
al. estimated lagged effects of health care spending on mortality 
and found that lagged health care spending decreased mortality 
amenable to health care (Heijink et al. 2012). Furthermore, in 
none of these studies is the issue of reverse causality addressed; 
sometimes it is not even mentioned. This implies that the effect 
of health care spending on mortality may be overestimated. 
An obvious limitation of all studies is that adjustments were 
made only for observable confounders or country-specific time-
invariant unobservable confounders in case of panel data. Finally, 
in most studies no explicit theoretical model was formulated to 
inform the empirical estimation strategy. 
 A study that did not use OECD data on total health care 
spending was the study by Barlow and Vissandjee (1999). They 
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used cross-sectional data on 77 countries for the year 1990 and 
regressed life expectancy at birth on total per capita health care 
spending (data on health care spending coming from various 
sources) while controlling for various confounders (daily intake 
of animal products, proportion of population with access to safe 
water, percentage of literate adults, percentage of population 
living in tropics). This study did not find any effect of health care 
spending on life expectancy.
Pharmaceutical expenditures 
Two studies using country level data from OECD countries focused 
on pharmaceutical spending. Both found pharmaceutical 
spending to be positively related to life expectancy. Miller and 
Frech (2002) used cross-sectional data on 18 OECD countries, 
mostly from the year 1998 (some data collected was from 1990). 
They regressed life expectancy at birth and at ages 40 and 
60 on pharmaceutical spending, while correcting for various 
confounders (GDP per capita, percentage of smokers, alcohol 
consumption, obesity). They found that pharmaceutical spending 
has a significant impact on most health outcomes. A 10% increase 
in pharmaceutical spending was found to increase life expectancy 
at age 60 by 0.6%. Shaw et al. (2002) used cross-sectional data 
on 19 OECD countries from 1997. They regressed life expectancy at 
ages 40, 60 and 65 on both current and delayed pharmaceutical 
spending while controlling for various confounders (e.g. GDP, 
alcohol & tobacco consumption). They found that both current 
and delayed pharmaceutical spending has a significant effect 
on life expectancy at age 40, 60 and 65. In this study a 10% 
increase in pharmaceutical spending was found to increase 
life expectancy at age 65 by 0.31%. In both studies no tests or 
sensitivity analyses were conducted to address reverse causality. 
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If we apply the estimates of these two studies to the Dutch 
context, life expectancy would have risen by approximately 0.2 
to 0.4 years between 2000 and 2010 as a result of an increase 
in pharmaceutical spending of only € 120 per capita. This would 
suggest that the increase in pharmaceutical spending was 
extremely cost-effective since the amount paid per life year 
gained is less than € 1,000.  
Health care reforms 
Although health systems differ in many respects between 
countries, only few studies have tried to assess the impact of 
health care reforms on life expectancy. An important reason for 
this is the difficulties in characterizing health systems in ways that 
are traceable to regression analysis. This is because these systems 
often combine many differing forms of provision and financing, 
i.e. no country fits perfectly into just one of the categories 
(Gerdtham and Jönsson 2000). Of the papers that have tried to 
estimate the impact of health care reforms, outcomes were mostly 
restricted to measures of health care output and did not include 
measures of mortality or life expectancy. However, Moreno-Serra 
and Wagstaff recently studied the impact of hospital payment 
reforms on health care outcomes in 28 countries in Europe and 
Central Asia over a longer time period (Moreno-Serra and Wagstaff 
2010). They estimated the impact of three major hospital payment 
methods: global budget, fee-for-service (FFS), and the patient 
based payment (PBP) system. They found that FFS and PBP both 
increased health care spending compared to a global budget. Of 
the two methods, only PBP appeared to have any beneficial effect 
on amenable mortality, but these results were very sensitive to 
model specification. For the Netherlands, these results seem to 
have little relevance as the reform from a global budget to fee-
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for-service coincided with the increase in life expectancy (Van de 
Vijsel et al. 2011). 
Studies using regional data
Studies using regional data have obvious advantages as, within a 
country, differences in terms of health care provision (and possibly 
also health) can expected to be smaller than between countries, 
plus there are fewer conversion problems associated with health 
care spending measurement. Studies using data from Canada and 
the UK have been published that have exploited regional variation 
in health and health care to investigate the effect of health care 
spending on mortality. 
Total health care and pharmaceutical expenditures
Two studies used time series data from different regions in Canada 
(Cremieux et al. 2005; Cremieux et al. 1999). One study (Cremieux 
et al. 2005) focused on pharmaceutical spending, while the other 
study (Cremieux et al. 1999) focused on total health care spending. 
In the latter paper, on total health care spending, data from 10 
provinces in Canada covering the 1978-1992 period were used. 
Infant mortality and life expectancy were regressed on public 
and private health care spending per capita while controlling 
for per capita number of physicians, GDP per capita, population 
density, unemployment and poverty rate, and alcohol and tobacco 
consumption. Province-specific dummy variables were included 
to capture differences between regions. Effects of health care 
spending were found to be significant for all outcome measures. 
A 10% increase in health care spending was estimated to increase 
male life expectancy by 0.05% and female life expectancy by 
0.024%. Applying these estimates to the Netherlands suggests 
that, of the increase in male life expectancy by 1.6 years between 
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2000 and 2010, 50% would have been the result of increased 
health care spending, implying an average cost of € 1,000 per life 
year gained. For women, the corresponding numbers would be 
0.8 years (39%) and € 1,900 per life year gained. 
 In the paper on pharmaceutical expenditures, cross-sectional 
time-series data for Canadian provinces from the 1975-1998 period 
were used. Infant mortality and life expectancy at birth and age 
65 were regressed on public drug spending per capita, private 
drug spending per capita, and non-drug health care spending per 
capita, while controlling for GDP per capita, population density, 
poverty rate, alcohol consumption, and tobacco consumption. 
Public and private drug spending were found to have a significant 
impact on most mortality indicators. A 10% increase in public 
drug spending per capita was estimated to increase both male 
and female life expectancy at birth by 0.1%. Applying these 
estimates to the Netherlands, this suggests that an increase 
in pharmaceutical spending by € 120 would have led to an 
increase of male/female life expectancy by 0.2/0.3 years between 
2000 and 2010. Again, this would suggest that the increase in 
pharmaceutical spending was extremely cost-effective as the 
amount paid per life year gained is below € 1,000. Total non-drug 
health care spending per capita had a significant negative effect 
on male mortality, but not on female mortality. In both papers 
by Cremieux et al. only contemporaneous effects of health care 
spending on mortality were estimated. No tests or sensitivity 
analyses were conducted to address reverse causality.
Disease specific health care expenditures 
Martin et al. published two studies (2008 and 2012) in which they 
used program budgeting data from about 300 Primary Care Trusts 
(PCT) in the UK to estimate the influence of health care spending 
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for different programs of care on mortality (programs of care refer 
to care for different disease groups). Each PCT covers a different 
geographical region within the UK; its task to allocate an annual 
lump sum budget allocated by the national ministry to different 
programs of care within its region. The models that Martin & al. 
estimate are derived from a theoretical model of the budgetary 
problem faced by a PCT. The theoretical model assumes that the 
PCT allocates this budget across health care programs to maximize 
a social welfare function. Using instrumental variable techniques 
to control for unobservable confounders, they estimated that costs 
per life year gained by health care programs range from £7,279 for 
circulatory problems, £13,931 for cancer, and £26,453 for diabetes. 
Cause-specific mortality under the age of 75 was used to calculate 
years of life lost, which were used as outcome variables in this 
study. Lagged influences were not considered in this study, and 
only instantaneous effects of health care spending on mortality 
were estimated. Using Dutch illness cost data from 2003 and 2007 
(Slobbe et al. 2006; Poos et al. 2008), we translated the findings 
from these studies to the Dutch context. In this period per capita 
health care spending on cancer increased from € 150 to € 210 and 
for cardiovascular disease from € 330 to € 420 (all expressed in 2007 
price level). This would translate to an increase in life expectancy 
of about 0.4 years due to increased spending on cardiovascular 
disease and 0.6 years due to increased spending on cancer. 
Health care reforms 
Regional data from the UK have also been used to investigate 
the consequences of introducing competition between hospitals 
in 2006. Two studies found that regions in which competition 
between hospitals was more fierce had slightly lower mortality 
without higher hospital expenditures (Cooper et al. 2011; Gaynor 
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et al. 2010). As the English system differs in many ways from the 
Dutch system it is not clear how to translate these findings to the 
Dutch context. They do, however, support the hypothesis that 
competition in health care may have beneficial effects on health. 
Studies using individual level data 
No studies are available that used individual-level data to 
investigate whether increased health care spending increases 
individual life expectancy. However, using individual level data, a 
few studies have tried to assess the costs and benefits (in terms of 
mortality) of an isolated technology. As mentioned in the previous 
chapter, the effectiveness (and sometimes also the costs) of new 
technology is usually established in clinical trials. However, as 
both costs and effects of a new technology may in real life differ 
from a trial, also the cost effectiveness of new technologies 
may be different in real life. As a consequence, the effect of 
introducing a new technology that increases health care spending 
does not automatically mirror the effects found in trials. An 
important study by David Cutler evaluated the costs and benefits 
of revascularization after a heart attack in the late 1980s (Cutler 
2007). He used individual data from the US, including medical 
records and insurance claims of persons who were admitted to 
a hospital with a heart attack in the 1986-1988 period. Cutler 
separately related the patients’ mortality and cumulative medical 
spending over a period of 17 years to a set of demographic and 
health control variables and a dummy variable, indicating 
whether the patient received a revascularization procedure or 
not. Instrumental variable techniques were used to correct for 
confounders. Cutler estimated that the greater survival for patients 
receiving revascularization translates into 1.1 years of additional 
life expectancy at an average cost of about $38,000. Thus, the 
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cost per year of life is $33,246. Major strengths of this research are 
the use of individual level data and the use of a good instrument 
(differential distance to a hospital) and the long follow-up 
period. This allowed addressing all the issues mentioned in the 
previous chapter. Findings from this study are relevant for the 
Dutch situation as survival after myocardial infarction has also 
improved in the Netherlands, partly due to improvements in 
revascularization (Nauta et al. 2011). However, it is not entirely 
clear how changes in clinical practice as described by Nauta et al. 
have influenced health care spending in the Netherlands. 
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4. Conclusions & discussion
Conclusions
While it is obvious that health care spending exerts a positive 
influence on life expectancy, it is less obvious whether marginal 
increases in health care spending have resulted in increased 
life expectancy. If we return to the research questions that we 
formulated in the introduction, we can conclude the following. 
Notwithstanding all methodology issues surrounding the 
estimates of empirical studies, it appears likely that increases 
in health care spending have contributed to the growth of life 
expectancy in Western countries. However, the strength of the 
effect remains uncertain, and the differences between sectors 
and mechanisms are unclear. Most studies looked at increases in 
overall health care spending and did not differentiate between 
the effects of different health care providers. Some studies 
focused on pharmaceutical spending and found quite strong 
effects on life expectancy, given the relatively low percentage of 
overall health care spending that is spent on pharmaceuticals. 
None of the studies focused on particular subgroups. In general, 
however, stronger effects of health care spending on mortality 
were found for newborns and the elderly, which is not that 
surprising given that mortality and health care consumption are 
highest in these groups. There is evidence that interventions at 
the micro level, such as the availability of medical technology, 
has exerted a positive influence on life expectancy. For instance, 
there is strong evidence that treatments for cardiovascular disease 
have contributed to the growth in life expectancy. However, the 
evidence base for a link between macro level interventions (such 
as health care system reforms) and life expectancy is weak. 
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 Our review revealed that a causal influence of marginal 
increases in health care spending has been difficult to 
demonstrate in empirical research. Randomized controlled clinical 
trials are unsuited for estimating the influence of health care 
spending on life expectancy. As a result, researchers have tried 
out a variety of methods and data sources to attempt to establish 
a causal link between health care spending and life expectancy. 
Many studies used data aggregated at country level from OECD 
countries. In these studies it is difficult to disentangle the effect of 
health care spending from the effects of confounders such as GDP 
on life expectancy or mortality. This was especially the case for 
studies that used cross-sectional data from a single year. Studies 
using country level panel data generally showed that there health 
care spending has a positive influence on life expectancy after 
controlling for several confounders. These findings were confirmed 
in studies using regional data from Canada and the UK. The review 
of empirical studies clearly demonstrated that it is difficult to 
demonstrate a causal influence of health care spending on life 
expectancy. Not a single study using country level or regional 
level data addressed all methodology issues (confounders, reverse 
causality, time lags). Only a study that used individual level data 
on revascularization (Cutler, 2007) addressed all methodology 
issues. However, as this study focused on an isolated technology 
(facilitating completeness), the relevance in terms of the effects 
of marginal health care spending are unclear. Our review also 
showed that some areas have hardly been researched. The 
question to what extent health systems influence mortality, for 
instance, is hardly researched. 
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Further research 
More research is needed to identify the mechanisms by which 
health care spending influences mortality. For instance, the role 
of reforms in the Dutch health care system is unclear (Van de 
Vijsel et al. 2011). To allow for better evaluation, it is advisable to 
implement health system changes in a phased manner instead 
of changing the entire system simultaneously countrywide. 
Furthermore, no studies have been published yet that investigated 
the effects of marginal increases in health care spending using 
individual level data. Linking different datasets, including health 
surveys and hospital registries such as made possible by Statistics 
Netherlands, may facilitate this.
Relevance for the Netherlands
Based on our review of empirical studies, we conclude that it is 
likely that increased health care spending has contributed to the 
recent increase in life expectancy in the Netherlands. Applying 
the estimates from published studies to the observed increase 
in health care spending in the Netherlands between 2000 and 
2010 would imply that 0.3% to almost 50% (1.6 years) of the 
increase in life expectancy may have been caused by increasing 
health care spending. An important reason for the wide range in 
such estimates is that they include all methodological problems 
highlighted in this paper. Therefore, these estimates should be 
handled with care. However, this wide range indicates that the 
counterfactual study by Meerding et al., which argued that 50% of 
the increase in life expectancy in the Netherlands since the 1950s 
can be attributed to medical care, should probably be interpreted 
as an upper bound.
  Better understanding of the causes and (distributional) 
consequences of increased longevity remains essential, also in 
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relation to other sectors. If the influence of health care spending 
on life expectancy is at the higher end of these estimates, 
increased health care spending will have had a clear impact 
on pension funds, since a one-year increase in life expectancy 
at retirement age increases pension liabilities by 3 to 4% (De 
Waegenaere et al. 2012). Based on this consequence for the 
pension sector, it is important that any evaluation of new medical 
technologies addresses the costs and benefits of increased life 
expectancy (Meltzer 1997). Currently, this is not done as evaluation 
of new technologies only includes a limited set of cost categories 
(Brouwer et al. 2008). Not only pension payments (which 
involves transfer of welfare), but also additional consumption 
and production during gained life years should be addressed. 
Finally, if there is indeed a link between marginal increases in 
health care spending and increased life expectancy, then the role 
of health care spending as a determinant of mortality could be 
acknowledged when forecasting life expectancy. 
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The influence of health care spending 
on life expectancy
Health care expenditures and life expectancy have both 
been rising in many countries, including in the Netherlands. 
However, it is unclear to what extent increased health care 
spending caused the increase in life expectancy. Researchers 
have tried a variety of methods and data sources to establish 
a causal link between health care spending and life 
expectancy. This Panel Paper by Pieter van Baal (EUR), Parida 
Obulqasim (EUR), Werner Brouwer (EUR), Wilma Nusselder 
(Erasmus MC) and Johan Mackenbach (Erasmus MC) reviews 
these methods and data sources in order to investigate 
whether there is a causal link or not.
